US FDA Approves STELARA in Children with Active PsA
The US Food and Drug Administration (FDA) has approved STELARA produced by Janssen Pharmaceutical Company of Johnson & Johnson, for the treatment of pediatric patients older than six years with active psoriatic arthritis (PsA). This rare disease affects around 8 percent of children and adolescents with chronic inflammatory arthritis. STELARA is a fully human monoclonal […]
Continue Reading